Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab.

摘要

Chronic urticaria is a severe skin disease characterized by itchy wheals and/or angioedema1'2 with an estimated lifetime prevalence of 3% to 5% in the general population.3'4 The current European Academy of Allergy and Clinical Immunology (EAACI)/Global Allergy and Asthma European Network (GA2LEN)/European Dermatology Forum (EDF)AVbrld Allergy Organization (WAO) treatment guidelines recommend nonsedat-ing Hi-antihistamines as first-line treatment, increasing their dosage as second-line treatment, and switching to another such antihistamine or adding a leukotriene antagonist as the third-line treatment.5 Thereafter, among several other fourth-line options including cyclosporine A,6 the guidelines suggest the possibility of using omalizumab, a humanized mAb that blocks the IgE receptor.7